CR20170361A - Forma de dosificación que incluye una solución sólida de drogas amorfas - Google Patents

Forma de dosificación que incluye una solución sólida de drogas amorfas

Info

Publication number
CR20170361A
CR20170361A CR20170361A CR20170361A CR20170361A CR 20170361 A CR20170361 A CR 20170361A CR 20170361 A CR20170361 A CR 20170361A CR 20170361 A CR20170361 A CR 20170361A CR 20170361 A CR20170361 A CR 20170361A
Authority
CR
Costa Rica
Prior art keywords
drugs
amorph
dosage form
solid solution
form including
Prior art date
Application number
CR20170361A
Other languages
English (en)
Inventor
Escobar Maria Del Pilar Noriega
Juan Mejia Marco Enrique San
Altamar Carlos Arturo Salazar
Restrepo Laura Uribe
Blanco Claudia Andrea Silvia
Original Assignee
Procaps S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56285892&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20170361(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Procaps S A filed Critical Procaps S A
Publication of CR20170361A publication Critical patent/CR20170361A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Quinoline Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La disolución de Ingredientes Farmacéuticos Activos en fundidos poliméricos juega un papel importante en la fabricación de fármacos que utilizan polímetros como excipientes. La cinética de disolución es esencial para diseñar el equipo de procesamiento, describir las condiciones operativas y definir las propiedades del material, por ejemplo, el par polímero-API adecuado
CR20170361A 2015-01-06 2015-09-10 Forma de dosificación que incluye una solución sólida de drogas amorfas CR20170361A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562100117P 2015-01-06 2015-01-06
US14/849,571 US20160193151A1 (en) 2015-01-06 2015-09-09 Dosage form incorporating an amorphous drug solid solution
PCT/US2015/049412 WO2016111725A1 (en) 2015-01-06 2015-09-10 Dosage form incorporating an amorphous dgug solid solution

Publications (1)

Publication Number Publication Date
CR20170361A true CR20170361A (es) 2018-01-25

Family

ID=56285892

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170361A CR20170361A (es) 2015-01-06 2015-09-10 Forma de dosificación que incluye una solución sólida de drogas amorfas

Country Status (13)

Country Link
US (1) US20160193151A1 (es)
EP (1) EP3242650A4 (es)
JP (2) JP2018507180A (es)
KR (1) KR20180102484A (es)
BR (1) BR112017014675A2 (es)
CA (1) CA2973218A1 (es)
CO (1) CO2017006788A2 (es)
CR (1) CR20170361A (es)
DO (1) DOP2017000162A (es)
EC (1) ECSP17046608A (es)
MX (1) MX2017008939A (es)
PE (1) PE20171308A1 (es)
WO (1) WO2016111725A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2619840C1 (ru) * 2016-09-21 2017-05-18 Общество с ограниченной ответственностью "Изварино Фарма" Фармацевтическая композиция для лечения ВИЧ-инфекции
EP3395336A1 (en) * 2017-04-28 2018-10-31 Nitto Denko Corporation Transdermal absorption preparation
US20200206139A1 (en) * 2017-09-11 2020-07-02 Board Of Regents, The University Of Texas System Compositions for the improved delivery of drugs
US20200405643A1 (en) * 2017-09-11 2020-12-31 Board Of Regents, The University Of Texas System Drug compositions containing porous carriers made by thermal or fusion-based processes
MX2020005517A (es) 2017-12-05 2020-11-09 Sunovion Pharmaceuticals Inc Formas cristalinas y metodos de produccion de las mismas.
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
WO2020072008A1 (en) * 2018-10-04 2020-04-09 Deva Holding Anonim Sirketi Novel solid dispersions of selinexor
SG11202113266YA (en) 2019-06-04 2021-12-30 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof
CN110585156B (zh) * 2019-10-24 2021-09-28 中国人民解放军军事科学院军事医学研究院 一种对乙酰氨基酚缓释制剂及其3d打印制备方法
US20230114357A1 (en) * 2020-03-17 2023-04-13 Rutgers,The State University Of New Jersey Continuous melt-coating of active pharmaceutical ingredients using surfactants for dissolution enhancement
EP4125923A1 (en) * 2020-04-01 2023-02-08 Board of Regents, The University of Texas System Pharmaceutical compositions of niclosamide
KR102594715B1 (ko) * 2020-04-17 2023-10-27 영남대학교 산학협력단 경구 생체 이용률이 증가된 니클로사마이드 함유 고체분산체 및 이의 제조방법
EP4236953A1 (en) * 2020-10-27 2023-09-06 ISP Investments LLC Method and system for predicting properties of amorphous solid dispersions using machine learning
GB2607554B (en) * 2021-03-04 2024-04-10 Reckitt Benckiser Health Ltd Novel composition
BR112023018888A2 (pt) * 2021-03-17 2023-12-05 Procaps Sa Placa distribuidora e segmento de cunha de enchimento, máquina para fabricar cápsulas, processo de moldagem em matriz rotativa, e, cápsula gelatinosa livre de bolhas de ar
CN114073679A (zh) * 2021-10-13 2022-02-22 广州汇元医药科技有限公司 一种塞来昔布组合物及其制备方法和应用
WO2023145869A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法
WO2023145871A1 (ja) * 2022-01-31 2023-08-03 住友精化株式会社 製剤用組成物の製造方法及び製剤の製造方法
WO2024092237A1 (en) * 2022-10-28 2024-05-02 Board Of Regents, The University Of Texas System Continuous mid-air 3-dimensional printing for pharmaceutical dosage forms

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00066B (me) * 1998-12-16 2010-06-10 Aventis Holdings Inc Antagonist serotonin receptora inkapsuliran u biorazgradivom polimeru i postupak njegovog dobijanja
WO2007003278A1 (en) * 2005-07-05 2007-01-11 Abbott-Gmbh & Co. Kg Composition and dosage form comprising a solid or semi-solid matrix
WO2008037809A1 (en) * 2006-09-29 2008-04-03 Abbott Gmbh & Co. Kg Transmucosal administration of fibrate compounds and delivery system therefor
WO2010130728A2 (de) * 2009-05-13 2010-11-18 Basf Se Feste pharmazeutischen zubereitungen enthaltend copolymere auf basis von polyethern in kombination mit wasserschwerlöslichen polymeren
EP2477606A1 (de) * 2009-09-18 2012-07-25 Basf Se Schnell lösliche feste pharmazeutische zubereitungen enthaltend amphiphile copolymere auf basis von polyethern in kombination mit hydrophilen polymeren
WO2011039675A2 (en) * 2009-09-30 2011-04-07 Pfizer Inc. Latrepirdine transdermal therapeutic dosage forms
EP2504033A1 (en) * 2009-11-24 2012-10-03 Basf Se Film-like pharmaceutical dosage forms
EP2536393B1 (en) * 2010-02-18 2014-04-16 AbbVie Deutschland GmbH & Co KG Test solvent for evaluating the compatibility of biologically active substances and graft copolymers
NZ605440A (en) * 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
RU2489445C2 (ru) * 2011-04-13 2013-08-10 Владимир Дмитриевич Артемьев Способ получения из топинамбура инулинсодержащего раствора, способ получения инулина и способ получения фруктоолигосахаридов на основе этого раствора

Also Published As

Publication number Publication date
EP3242650A1 (en) 2017-11-15
BR112017014675A2 (pt) 2018-03-13
CA2973218A1 (en) 2016-07-14
WO2016111725A1 (en) 2016-07-14
MX2017008939A (es) 2018-11-09
EP3242650A4 (en) 2018-08-01
ECSP17046608A (es) 2017-07-31
KR20180102484A (ko) 2018-09-17
JP2021059540A (ja) 2021-04-15
DOP2017000162A (es) 2018-11-15
JP2018507180A (ja) 2018-03-15
US20160193151A1 (en) 2016-07-07
CO2017006788A2 (es) 2017-07-19
PE20171308A1 (es) 2017-09-05

Similar Documents

Publication Publication Date Title
CR20170361A (es) Forma de dosificación que incluye una solución sólida de drogas amorfas
CL2018000706A1 (es) Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer.
CL2016000952A1 (es) Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b
NZ734233A (en) Pharmaceutical compositions comprising meloxicam
SV2017005489A (es) Terapias de combinación para el tratamiento de cánceres
CL2018002758A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue.
ECSP15004752A (es) Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
GT201700150A (es) Derivados de glucagón con estabilidad mejorada
CR20150637A (es) Tratamiento de enfermedades miopaticas y neurodegenerativas por agregación de proteina mediante administración parenteral
EA201501164A1 (ru) Твердая фармацевтическая лекарственная форма
EA201692392A1 (ru) Новая лекарственная форма мелоксикама
BR112014032583A8 (pt) forma farmacêutica para liberação prolongada de substâncias ativas e seu processo de produção
ECSP16086247A (es) (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina
AR101901A1 (es) Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod
AR101673A1 (es) Composición para el tratamiento de neuropatías y del dolor neuropático
CL2017001680A1 (es) Composición farmacéutica para el tratamiento de enfermedades gastrointestinales
ECSP15033649A (es) Un medicamento combinado que comprende fenilefrina y paracetamol
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
MX2021003230A (es) Composiciones farmaceuticas que comprenden meloxicam.
AR103267A1 (es) Método para preparación de liposomas que contienen un ingrediente farmacéutico activo
BR112017014295A2 (pt) composição farmacêutica.
CO2018010142A2 (es) Proceso de preparación de fórmulas solidas de mesalazina
EA201891848A1 (ru) Фармацевтическая композиция для применения в лечении фиброза
UY35989A (es) Uso de paricalcitol en el tratamiento de la anemia inflamatoria